• Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page

BridgeBio Stock Makes A Bullish Move On Dwarfism Treatment Results

cafead

Administrator
Staff member
  • cafead   Jun 04, 2024 at 11:42: AM
via BridgeBio (BBIO) stock rose early Tuesday after the drugmaker's growth disorder treatment topped Wall Street's expectations in a Phase 2 study.

The biotech company tested a daily pill in patients with achondroplasia, a genetic disease that affects the limbs and spine. Achondroplasia is the most common cause of dwarfism.

article source
 

<